Location History:
- Kronberg/Taunus, DE (1992 - 1993)
- Kronberg, DE (1995 - 2002)
Company Filing History:
4 out of 6,662 
2 out of 330 
1 out of 18 Years Active: 1992-2002
Title: The Innovations of Gabriele Wiemer: A Pioneer in Pharmaceutical Patents
Introduction: Gabriele Wiemer, based in Kronberg, Germany, is a notable inventor with an impressive portfolio of eight patents. His work primarily focuses on developing pharmaceutical solutions that target critical health challenges, particularly in neurodegenerative diseases.
Latest Patents: Among his most recent patents are "1-(p-thienylbenzyl)imidazoles as agonists of angiotensin (1-7) receptors," which explores new avenues for treating cardiovascular diseases. Additionally, his research into "the use of peptidic bradykinin antagonists for the treatment and prevention of Alzheimer's disease" has paved the way for innovative pharmaceutical interventions. This invention emphasizes the potential of certain peptides, such as H-D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg-OH (HOE 140) and their physiologically tolerable salts, in combating the adverse effects of the Alzheimer's protein amyloid (β/A4) on endothelial cells.
Career Highlights: Gabriele Wiemer has made significant contributions to the pharmaceutical sector during his tenure at esteemed companies such as Hoechst Aktiengesellschaft and Aventis Pharma Deutschland, GmbH. His expertise in drug development and innovative research has not only advanced the field of pharmacology but has also established him as a leading inventor in the industry.
Collaborations: Throughout his career, Wiemer has collaborated with other prominent researchers, including Holger Heitsch and Hansjorg Urbach. These partnerships have facilitated the development of groundbreaking pharmacological products and have enhanced the effectiveness of their research efforts.
Conclusion: Gabriele Wiemer's dedication to innovation in the pharmaceutical industry and his extensive patent portfolio illustrate his significant impact on modern medicine. His work continues to inspire future research and development in tackling crucial health challenges, particularly in the area of neurodegenerative diseases. As the landscape of pharmaceuticals evolves, Wiemer's contributions will undoubtedly remain influential.